- Home
- CMMB vs JZ Comparison
CMMB vs JZ Comparison
Compare CMMB & JZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- JZ
- Stock Information
- Founded
- CMMB 2004
- JZ 2011
- Country
- CMMB Israel
- JZ China
- Employees
- CMMB N/A
- JZ N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- JZ Other Consumer Services
- Sector
- CMMB Health Care
- JZ Real Estate
- Exchange
- CMMB Nasdaq
- JZ Nasdaq
- Market Cap
- CMMB 23.6M
- JZ 26.7M
- IPO Year
- CMMB N/A
- JZ 2022
- Fundamental
- Price
- CMMB $1.20
- JZ $0.80
- Analyst Decision
- CMMB Strong Buy
- JZ
- Analyst Count
- CMMB 2
- JZ 0
- Target Price
- CMMB $9.00
- JZ N/A
- AVG Volume (30 Days)
- CMMB 167.2K
- JZ 9.0K
- Earning Date
- CMMB 05-08-2025
- JZ 01-01-0001
- Dividend Yield
- CMMB N/A
- JZ N/A
- EPS Growth
- CMMB N/A
- JZ N/A
- EPS
- CMMB N/A
- JZ N/A
- Revenue
- CMMB N/A
- JZ $50,810,288.00
- Revenue This Year
- CMMB N/A
- JZ N/A
- Revenue Next Year
- CMMB N/A
- JZ N/A
- P/E Ratio
- CMMB N/A
- JZ N/A
- Revenue Growth
- CMMB N/A
- JZ N/A
- 52 Week Low
- CMMB $0.58
- JZ $0.53
- 52 Week High
- CMMB $2.55
- JZ $2.34
- Technical
- Relative Strength Index (RSI)
- CMMB 50.27
- JZ 48.18
- Support Level
- CMMB $1.08
- JZ $0.77
- Resistance Level
- CMMB $1.25
- JZ $0.90
- Average True Range (ATR)
- CMMB 0.11
- JZ 0.10
- MACD
- CMMB 0.04
- JZ 0.01
- Stochastic Oscillator
- CMMB 83.65
- JZ 47.27
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About JZ Jianzhi Education Technology Group Company Limited
Jianzhi Education Technology Group Co Ltd engages in developing educational content to fulfill the massive demand for high-quality, professional development training resources in China. The company and its subsidiaries VIE and VIEs generate subscription revenue through selling subscriptions to online learning platforms, higher education institutions, and other institutional customers under a B2B2C model mainly through the platform of Sentu Academy; offering subscriptions concerning educational content in mobile video packages directly to end users under a B2C model through the platforms such as Fish Learning or Light Class, etc. It has two operating segments: Educational content services and other services and IT-related solution services.